Hangzhou Reprogenix Bio

Hangzhou Reprogenix Biopharmaceutical is a clinical-stage biotechnology company based in Hangzhou, China, focused on developing innovative oncolytic virus therapies for cancer treatment. The company utilizes its proprietary oncolytic Herpes Simplex Virus (o-HSV) platform to create therapeutic candidates that selectively infect and destroy tumor cells while inducing a robust systemic immune response. Its lead program, RGX-101, is an engineered HSV-1 virus currently in Phase 1/2 clinical trials for patients with advanced solid tumors. Reprogenix's pipeline also includes next-generation viral vectors designed to deliver therapeutic payloads directly into the tumor microenvironment. Backed by prominent investors like Qiming Venture Partners and Lilly Asia Ventures, the company aims to establish a new standard of care in immuno-oncology. The company's research and development efforts are centered on optimizing viral replication and enhancing the immunogenicity of the tumor microenvironment.